Infigratinib

Generic Name: Infigratinib

Brand Names: Truseltiq

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₃₁Cl_₂N_₇O_₃

CAS Number: 872511-34-7

Unique Ingredient Identifier: A4055ME1VK

Background: Infigratinib is a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor. By inhibiting the FGFR pathway, which is often aberrated in cancers such as cholangiocarcinoma, infigratinib suppresses tumour growth. Cholangiocarcinoma is the most common primary malignancy affecting the biliary tract and the second most common primary hepatic malignancy. Infi...

Indication: Infigratinib is indicated for the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by an FDA-approved test.

Associated Conditions: Unresectable, locally advanced Cholangiocarcinomas, Unresectable, metastatic Cholangiocarcinomas

Associated Therapies: -

Clinical Trials

BridgeBio Grows Up, Trims Pipeline as It Leans Into Late-Stage Assets

BridgeBio, founded in 2015, has two products on the market and another awaiting FDA decision by November. The company is spinning out assets into new entities, discontinuing a gene therapy program, and focusing on late-stage programs in transthyretin amyloid cardiomyopathy and achondroplasia. BridgeBio aims to have six approved products by its tenth birthday, with a focus on commercializing its later-stage pipeline. The company’s success hinges on the approval and market performance of acoramidis for ATTR-CM and infigratinib for achondroplasia.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy